Large-scale expansion of human umbilical cord mesenchymal stem cells in human platelet lysate as a substitute of fetal bovine serum

doi:10.3969/j.issn.2095-4344.2014.10.010

Abstract

Abstract:

BACKGROUND: Classic media and fetal bovine serum are commonly used in the culture of umbilical cord mesenchymal stem cells, but the potential risk of serum culture limits its clinical application.
OBJECTIVE: To use human platelet lysate alternative to fetal bovine serum for large-scale production of mesenchymal stem cells for therapeutic applications.
METHODS: Human platelet lysate was prepared by repeated freezing and thawing, centrifugation, filtration, and concentration. Human umbilical cord mesenchymal stem cells were cultured in Iscove’s Modified Dulbecco’s Medium containing 5% concentrated platelet lysate (experimental group) or 10% fetal bovine serum (control group). After separation and enzymatic digestion, human umbilical cord mesenchymal stem cells were subcultured at a concentration of 3 000/cm² up to the fifth generation. Then, cell morphology and diameter, immune phenotype, osteogenic and adipogenic differentiation, and cloning efficiency were detected and compared between two groups.
RESULTS AND CONCLUSION: Human umbilical cord mesenchymal stem cells cultivated in human platelet lysate-supplemented media showed a smaller size and more elongated morphology than those in fetal bovine serum-supplemented media. Colony forming unit-fibroblast analyses further showed no significant differences in colony efficiency. Human umbilical cord mesenchymal stem cells cultivated in human platelet
lysate-supplemented media showed an increase of proliferation capacity; whereas, similar immunophenotypes remained in the two groups. In vitro assays revealed intact differentiation potential. Moreover, human umbilical cord mesenchymal stem cells cultivated in human platelet lysate-supplemented media showed a significantly higher capacity to differentiate towards osteocytes, indicating human platelet lysate is an alternative to fetal bovine serum for low-density production of mesenchymal stem cells for therapeutic applications.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: stem cells, mesenchymal stem cells, culture media, adipogenesis, actihaemyl

CLC Number:

R394.2

Li Bing-yao, Wu Xiao-yun, Wu Yan. Large-scale expansion of human umbilical cord mesenchymal stem cells in human platelet lysate as a substitute of fetal bovine serum[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(10): 1539-1546.

Figures/Tables 5

References

[1]Otto WR, Wright NA. Mesenchymal stem cells: from experiment to clinic. Fibrogenesis Tissue Repair. 2011; 4:20.

[2]Spitkovsky D, Hescheler J. Adult mesenchymal stromal stem cells for therapeutic applications. Minim Invasive Ther Allied Technol. 2008;17(2):79-90.

[3]Tantrawatpan C, Manochantr S, Kheolamai P, et al. Pluripotent gene expression in mesenchymal stem cells from human umbilical cord wharton's jelly and their differentiation potential to neural-like cells. J Med Assoc Thai. 2013;96: 1208-1217.

[4]Luo X, Yao RS, Song H, et al. [Study on human umbilical cord mesenchymal stem cells transplantation in treatment of stress urinary incontinence in rats]. Zhonghua Fu Chan Ke Za Zhi. 2013;48:579-583.

[5]Liu LY, Chai JK, Duan HJ, et al. [Comparison of different methods for the isolation of human umbilical cord mesenchymal stem cells]. Zhonghua Yi Xue Za Zhi. 2013;93:2592-2596.

[6]Bai C, Gao Y, Li Q, et al. Differentiation of chicken umbilical cord mesenchymal stem cells into beta-like pancreatic islet cells. Artif Cells Nanomed Biotechnol. 2013.

[7]van der Valk J, Brunner D, De Smet K, et al. Optimization of chemically defined cell culture media--replacing fetal bovine serum in mammalian in vitro methods. Toxicol In Vitro. 2010; 24(4):1053-1063.

[8]Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther. 2004;9(5): 747-756.

[9]Poloni A, Maurizi G, Serrani F, et al. Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate. Cell Prolif. 2012;45(1):66-75.

[10]Gottipamula S, Sharma A, Krishnamurthy S, et al. Human platelet lysate is an alternative to fetal bovine serum for large-scale expansion of bone marrow-derived mesenchymal stromal cells. Biotechnol Lett. 2012;34(7):1367-1374.

[11]Azouna NB, Jenhani F, Regaya Z, et al. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther. 2012;3(1):6.

[12]Ma HY, Yao L, Yu YQ, et al. An Effective and Safe Supplement for Stem Cells Expansion ex vivo - Cord Blood Serum. Cell Transplant. 2012;21(5):857-869.

[13]Huang L, Critser PJ, Grimes BR, et al. Human umbilical cord blood plasma can replace fetal bovine serum for in vitro expansion of functional human endothelial colony-forming cells. Cytotherapy. 2011;13(6):712-721.

[14]Tekkatte C, Vidyasekar P, Kapadia NK, et al. Enhancement of adipogenic and osteogenic differentiation of human bone-marrow-derived mesenchymal stem cells by supplementation with umbilical cord blood serum. Cell Tissue Res. 2012;347(2):383-395.

[15]Wu KH, Tsai C, Wu HP, et al. Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: Enhance hematopoiesis after cord blood transplantation. Cell Transplant. 2013;22:2041-2051.

[16]Kishimoto S, Ishihar, M, Mori Y, et al. Effective expansion of human adipose-derived stromal cells and bone marrow-derived mesenchymal stem cells cultured on a fragmin/protamine nanoparticles-coated substratum with human platelet-rich plasma. J Tissue Eng Regen Med. 2012. [Epub ahead of print]

[17]Hartmann I, Hollweck T, Haffner S, et al. Umbilical cord tissue-derived mesenchymal stem cells grow best under GMP-compliant culture conditions and maintain their phenotypic and functional properties. J Immunol Methods. 2010;363(1):80-89.

[18]Hou ZL, Liu Y, Mao XH, et al. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. Cell Adh Migr. 2013.

[19]Li L, Liu S, Xu Y, et al. Human umbilical cord-derived mesenchymal stem cells downregulate inflammatory responses by shifting the treg/th17 profile in experimental colitis. Pharmacology. 2013;92:257-264.

[20]Li T, Ma Q, Ning M, et al. Cotransplantation of human umbilical cord-derived mesenchymal stem cells and umbilical cord blood-derived cd34 cells in a rabbit model of myocardial infarction. Mol Cell Biochem. 2013.

[21]Meng HB, Gong J, Zhou B, et al. Therapeutic effect of human umbilical cord-derived mesenchymal stem cells in rat severe acute pancreatitis. Int J Clin Exp Pathol. 2013;6: 2703-2712.

[22]Wang H, Qiu X, Ni P, et al. Immunological characteristics of human umbilical cord mesenchymal stem cells and the therapeutic effects of their transplantion on hyperglycemia in diabetic rats. Int J Mol Med. 2014;33:263-270.

[23]Zhang X, Zhang Q, Li W, et al. Therapeutic effect of human umbilical cord mesenchymal stem cells on neonatal rat hypoxic-ischemic encephalopathy. J Neurosci Res. 2014; 92:35-45.

[24]Liu L, Zhao X, Li P, et al. A novel way to isolate MSCs from umbilical cords. Eur J Immunol. 2012;42(8):2190-2193.

[25]Nekanti U, Mohanty L, Venugopal P, et al. Optimization and scale-up of Wharton's jelly-derived mesenchymal stem cells for clinical applications. Stem Cell Res. 2010;5(3):244-254.

[26]Schallmoser K, Rohde E, Reinisch A, et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods. 2008;14(3):185-196.

[27]Doucet C, Ernou I, Zhang Y, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005;205(2):228-236.

[28]Weibrich G, Kleis WK, Hafner G, et al. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg. 2002;30(2):97-102.

[29]Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. 2004;114(6): 1502-1508.

[30]Ng F, Boucher S, Koh S, et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood. 2008;112(2):295-307.

[31]Chieregato K, Castegnaro S, Madeo D, et al. Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells derived from adipose tissue. Cytotherapy. 2011;13(8): 933-943.

[32]van Geemen D, Riem Vis PW, Soekhradj-Soechit S, et al. Decreased mechanical properties of heart valve tissue constructs cultured in platelet lysate as compared to fetal bovine serum. Tissue Eng Part C Methods. 2011;17(5): 607-617.

[33]Rauch C, Feifel E, Amann EM, et al. Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. ALTEX. 2011;28(4):305-316.

[34]Naaijkens BA, Niessen HW, Prins HJ, et al. Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications. Cell Tissue Res. 2012;348(1):119-130.

[35]Xia W, Li H, Wang Z, et al. Human platelet lysate supports ex vivo expansion and enhances osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Cell Biol Int. 2011;35(6):639-643.

[36]Gottipamula S, Sharma A, Krishnamurthy S, et al. Human platelet lysate is an alternative to fetal bovine serum for large-scale expansion of bone marrow-derived mesenchymal stromal cells. Biotechnol Lett. 2012;34:1367-1374.

[37]Xia W, Li H, Wang Z, et al. Human platelet lysate supports ex vivo expansion and enhances osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Cell Biol Int. 2011;35:639-643.

[38]Mimura S, Kimura N, Hirata M, et al. Growth factor-defined culture medium for human mesenchymal stem cells. Int J Dev Biol. 2011;55:181-187.

[39]Maruyama T, Mirando AJ, Deng CX, et al. The balance of wnt and fgf signaling influences mesenchymal stem cell fate during skeletal development. Sci Signal. 2010;3:40.

[40]吕江涛,田少奇,孙康,等. 血小板裂解液对人脐带间充质干细胞体外成骨分化的影响[J]. 中国组织工程研究，2012,16(41): 7637-7641.

[41]冯学涛.血小板裂解液对人脐带间充质干细胞体外成软骨分化的影响[D].青岛大学,2012.

[42]冯学涛,田少奇,孙康,等.血小板裂解液对人脐带间充质干细胞体外成软骨分化的影响[J].中国修复重建外科杂志,2011,25(10): 1250-1255.

[43]孙伟雪,孙康,田少奇,等.血小板裂解液对脐带间充质干细胞增殖与分化的影响[J].中国组织工程研究与临床康复,2011, 15(27): 5100-5103.

[44]陈博. 血小板裂解液对牙源性间充质干细胞的生物学影响[D]. 第四军医大学,2012.

[45]宋会平,王志强,赵亚平,等.血小板裂解液对大鼠骨髓间充质干细胞生长的影响[J].中国组织工程研究与临床康复,2008, 12(21): 4031-4034.

[46]陈璐.血小板血浆与血小板裂解液对骨髓基质干细胞增殖影响的比较[D].河北联合大学,2011.

[47]董晶,聂李平,周宇,等.血小板裂解液快速扩增人羊膜来源间充质干细胞[J].微循环学杂志,2012,22(4):1-16.

[48]许茹,夏文杰,戎霞,等.人血小板裂解液替代胎牛血清促进骨髓间质干细胞的增殖[J].南方医科大学学报,2011,31(8):1396-1400.

[49]王贞,夏文杰,叶欣,等.人血小板裂解液对骨髓间质干细胞成骨成脂分化的影响[J].中国输血杂志,2011,24(10):853-857.